Literature DB >> 7824507

Transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor expression in normal and diseased human adrenal cortex by immunohistochemistry and in situ hybridization.

H Sasano1, T Suzuki, S Shizawa, K Kato, H Nagura.   

Abstract

Because epidermal growth factor (EGF), transforming growth factor-alpha (TGF-alpha), and epidermal growth factor receptor (EGFR) have been implicated in the regulation of adrenocortical function, we used immunohistochemistry and in situ hybridization of EGF and TGF-alpha to study 41 specimens of human adrenal cortex, including 10 normal specimens, 15 aldosteronomas, five Cushing's adenomas, six adrenocortical incidentalomas, and five carcinomas to determine what role these growth factors play in controlling human adrenocortical function. Neither immunoreactivity nor mRNA hybridization signals to EGF was detected in any specimens, and EGF therefore may exert its effects on adrenal function as an endocrine hormone. TGF-alpha expression was detected at both protein and mRNA levels in normal and neoplastic adrenal cortex, demonstrating that TGF-alpha is synthesized locally in human adrenal cortex. TGF-alpha expression was observed in the cells with increased steroidogenesis, including compact tumor cells and zona fasciculata cells with lipid depletion, but did not necessarily correlate with production sites of any specific steroid hormone. EGFR immunoreactivity was more widely distributed than TGF-alpha immunoreactivity. Both TGF-alpha and EGFR expression were markedly elevated in adrenocortical carcinomas. TGF-alpha and EGFR thus appear to be involved in biological function in both normal and neoplastic human adrenal cortex. In addition, TGF-alpha and EGFR may play important roles in some biological features of adrenocortical malignancy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7824507

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  8 in total

Review 1.  Targeted therapies for adrenocortical carcinoma: IGF and beyond.

Authors:  Michael J Demeure; Kimberly J Bussey; Lawrence S Kirschner
Journal:  Horm Cancer       Date:  2011-12       Impact factor: 3.869

2.  Emerging therapy for adrenocortical carcinoma.

Authors:  Rachel D Aufforth; Naris Nilubol
Journal:  Int J Endocr Oncol       Date:  2014

Review 3.  Roles of the pathologist in evaluating surrogate markers for medical therapy in adrenocortical carcinoma.

Authors:  Hironobu Sasano; Fumitoshi Satoh; Yasuhiro Nakamura
Journal:  Endocr Pathol       Date:  2014-12       Impact factor: 3.943

Review 4.  Discerning malignancy in resected adrenocortical neoplasms.

Authors:  H Sasano; T Suzuki; T Moriya
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

Review 5.  Current and emerging therapies for advanced adrenocortical carcinoma.

Authors:  Lyndal J Tacon; Ruth S Prichard; Patsy S H Soon; Bruce G Robinson; Roderick J Clifton-Bligh; Stan B Sidhu
Journal:  Oncologist       Date:  2011-01-06

6.  An analysis of potential surrogate markers of target-specific therapy in archival materials of adrenocortical carcinoma.

Authors:  Megumi Nakamura; Yasuhiro Miki; Jun-Ichi Akahira; Ryo Morimoto; Fumitoshi Satoh; Shigeto Ishidoya; Yoichi Arai; Takashi Suzuki; Yutaka Hayashi; Hironobu Sasano
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

7.  Adrenal cortical neoplasms: a study of clinicopathological features related to epidermal growth factor receptor gene status.

Authors:  Jing Zhang; Cuiping Wang; Jie Gao; Jian Sun; Xuan Zeng; Shafei Wu; Zhiyong Liang
Journal:  Diagn Pathol       Date:  2014-01-23       Impact factor: 2.644

8.  Acquisition order of Ras and p53 gene alterations defines distinct adrenocortical tumor phenotypes.

Authors:  Maryline Herbet; Aude Salomon; Jean-Jacques Feige; Michaël Thomas
Journal:  PLoS Genet       Date:  2012-05-10       Impact factor: 5.917

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.